Indian J Med Microbiol Close
 

Figure 1: Schematic representation of the strategy used to selectively amplify genetic regions harboring polymorphisms for sequencing. (a) MYBPC3 - rs36212066 (25 bp deletion, intron 32),b) SLCO1B1 - rs4149056 (c. 521T > C, exon 6),c) VKORC1 - rs9923231 (c.−1639 G > A, promoter)d) CYP2C9 alleles, - CYP2C9*13 - rs72558187 (c. 269T > C, exon 2), CYP2C9*2-rs28371674 (c. 430C > T, exon 3) and CYP2C9*3 rs1057910 (c. 1075A > C, exon 7), (e) CYP2C19 alleles, - CYP2C19*3 rs4986893 (c. 636G > A, exon 4) and CYP2C19*2 rs4244285 (c. 681G > A, exon 5)

Figure 1: Schematic representation of the strategy used to selectively amplify genetic regions harboring polymorphisms for sequencing. (a) <i>MYBPC3</i> - rs36212066 (25 bp deletion, intron 32),b) <i>SLCO1B1</i> - rs4149056 (c. 521T > C, exon 6),c) <i>VKORC</i>1 - rs9923231 (c.−1639 G > A, promoter)d) <i>CYP2C9</i> alleles, - <i>CYP2C9</i>*13 - rs72558187 (c. 269T > C, exon 2), <i>CYP2C9*</i>2-rs28371674 (c. 430C > T, exon 3) and <i>CYP2C9*</i>3 rs1057910 (c. 1075A > C, exon 7), (e) <i>CYP2C19</i> alleles, - <i>CYP2C19*</i>3 rs4986893 (c. 636G > A, exon 4) and <i>CYP2C19*</i>2 rs4244285 (c. 681G > A, exon 5)